JP7757298B2 - 新規な大環状化合物、それを製造するための方法及びそれを含有する医薬組成物 - Google Patents

新規な大環状化合物、それを製造するための方法及びそれを含有する医薬組成物

Info

Publication number
JP7757298B2
JP7757298B2 JP2022551283A JP2022551283A JP7757298B2 JP 7757298 B2 JP7757298 B2 JP 7757298B2 JP 2022551283 A JP2022551283 A JP 2022551283A JP 2022551283 A JP2022551283 A JP 2022551283A JP 7757298 B2 JP7757298 B2 JP 7757298B2
Authority
JP
Japan
Prior art keywords
methyl
dioxo
ethyl
ppm
general procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022551283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515572A (ja
JP2023515572A5 (https=
Inventor
ヴェーバー，チャバ
セードルフ，クラウス
デュラン，ディディエ
ジュリス，マリオ
キッシュ，アールパード
マダラス，ゾルターン
モルナール，マーク
ニェルゲシュ，ミクロス
ルダソワ，モニカ
サピ，アティッラ
ベルガー，シルヴィ
デュヴィヴィエ，ヴァレリー
マルティニー，ヴィルジニー
テレ，イザベル
ヴィンソン，セドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of JP2023515572A publication Critical patent/JP2023515572A/ja
Publication of JP2023515572A5 publication Critical patent/JP2023515572A5/ja
Application granted granted Critical
Publication of JP7757298B2 publication Critical patent/JP7757298B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022551283A 2020-02-28 2021-02-26 新規な大環状化合物、それを製造するための方法及びそれを含有する医薬組成物 Active JP7757298B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305207.1 2020-02-28
EP20305207 2020-02-28
PCT/EP2021/054780 WO2021170774A1 (en) 2020-02-28 2021-02-26 New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
JP2023515572A JP2023515572A (ja) 2023-04-13
JP2023515572A5 JP2023515572A5 (https=) 2024-03-04
JP7757298B2 true JP7757298B2 (ja) 2025-10-21

Family

ID=70977485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551283A Active JP7757298B2 (ja) 2020-02-28 2021-02-26 新規な大環状化合物、それを製造するための方法及びそれを含有する医薬組成物

Country Status (12)

Country Link
US (1) US20230097678A1 (https=)
EP (1) EP4110776A1 (https=)
JP (1) JP7757298B2 (https=)
KR (1) KR20220148851A (https=)
CN (1) CN115151538B (https=)
AR (1) AR121435A1 (https=)
AU (1) AU2021226994A1 (https=)
BR (1) BR112022016286A2 (https=)
IL (1) IL295595B1 (https=)
MX (1) MX2022010673A (https=)
TW (1) TWI891735B (https=)
WO (1) WO2021170774A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014680A (es) 2019-05-31 2022-04-06 Ube Corp Derivado de benzotriazol.
CN114028374A (zh) * 2021-12-01 2022-02-11 江苏省人民医院（南京医科大学第一附属医院） 富马酸二甲酯在制备用于保护胰岛β细胞功能的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503786A (ja) 2013-12-18 2017-02-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーター

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503786A (ja) 2013-12-18 2017-02-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーター

Also Published As

Publication number Publication date
TWI891735B (zh) 2025-08-01
US20230097678A1 (en) 2023-03-30
IL295595A (en) 2022-10-01
AU2021226994A1 (en) 2022-09-08
BR112022016286A2 (pt) 2022-12-13
AR121435A1 (es) 2022-06-08
CN115151538B (zh) 2026-02-27
CA3170840A1 (en) 2021-09-02
KR20220148851A (ko) 2022-11-07
IL295595B1 (en) 2026-01-01
CN115151538A (zh) 2022-10-04
JP2023515572A (ja) 2023-04-13
TW202144367A (zh) 2021-12-01
EP4110776A1 (en) 2023-01-04
WO2021170774A1 (en) 2021-09-02
MX2022010673A (es) 2022-09-23

Similar Documents

Publication Publication Date Title
US10081625B2 (en) 5-methyl-1,2,4-oxadiazol-3-yl compounds
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
EP2603513B1 (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator
CA3100795A1 (en) Pyridinyl and pyrazinyl-(aza)indolsulfonamides
JP2020524158A (ja) Ｓｓａｏ阻害剤
AU2023200994A1 (en) FXR (NR1H4) modulating compounds
WO1999051572A1 (en) Sulfonamide derivatives
KR20240073108A (ko) Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄
JP7757298B2 (ja) 新規な大環状化合物、それを製造するための方法及びそれを含有する医薬組成物
KR20210082466A (ko) 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물
CA2696237A1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
CN115667243B (zh) 作为nrf2活化剂的四氢异喹啉化合物
US20220356194A1 (en) Process for preparing benzothiophen-2yl boronate
US20150175603A1 (en) Tricyclic compounds as kat ii inhibitors
CN119487029A (zh) N6-腺苷-甲基转移酶protac及其使用方法
JP2025504791A (ja) ヒドロキシフェニル部分を含む化合物及びその使用
CA3170840C (en) Macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
EA050508B1 (ru) Новые макроциклические соединения, способ их получения и содержащие их фармацевтические композиции
EP2396319B1 (fr) Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
Xu et al. Design, synthesis and biological evaluation of selective histone deacetylase 6 (HDAC6) inhibitors bearing benzoindazole or pyrazoloindazole scaffold as surface recognition motif
EP4342530A1 (en) Sortilin modulators
HK40078242A (en) New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
CN112209896A (zh) 噻唑烷二酮衍生物以及包含其的药物组合物
JP2010180178A (ja) 二環式アミノピラゾールアミド誘導体
CA3256688A1 (en) BENZOTRIAZOLE COMPOUND

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251008

R150 Certificate of patent or registration of utility model

Ref document number: 7757298

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150